Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Transcenta Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Transcenta 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Jacobio Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Jacobio Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
ImmuneOnco Biopharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
ImmuneOnco Biopharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Antengene Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Antengene 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Gastric Cancer Indication Strategy Report 2026: CLDN18.2, HER2, Trials and Deal Outlook
20 July 2026
A 2026 gastric cancer strategy report covering global burden, CLDN18.2 and HER2 biology, clinical competition, recent transactions and portfolio positioning.
Latest Hotspot
8 min read
Hepatocellular Carcinoma Indication Strategy Report 2026: PD-1/VEGF Biology, Trials and Deal Outlook
20 July 2026
A 2026 hepatocellular carcinoma strategy report covering liver-disease burden, PD-1 and VEGF biology, clinical competition, recent transactions and R&D positioning.
Latest Hotspot
8 min read
Cholangiocarcinoma Indication Strategy Report 2026: FGFR2, IDH1, Trials and Deal Outlook
20 July 2026
A 2026 cholangiocarcinoma strategy report covering disease burden, FGFR2 and IDH1 biology, clinical competition, recent licensing and portfolio positioning.
Latest Hotspot
8 min read
Esophageal Cancer Indication Strategy Report 2026: PD-1, HER2, Trials and Deal Outlook
20 July 2026
A 2026 esophageal cancer strategy report covering global burden, PD-1 and HER2 biology, clinical competition, transactions and portfolio positioning.
Latest Hotspot
8 min read
Clear Cell Renal Cell Carcinoma Indication Strategy Report 2026: VHL/HIF-2α, Trials and Deal Outlook
20 July 2026
A 2026 clear cell renal cell carcinoma strategy report covering burden, VHL and HIF-2α biology, clinical competition, transactions and portfolio positioning.
Latest Hotspot
8 min read
Brii Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Brii Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Clover Biopharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Clover Biopharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Walvax Biotechnology Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Walvax Biotechnology 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.